

Supplementary Table 1. Characteristics of Excluded Studies

No	Study	Reason for exclusion
1	Stern 1966	Medication is not on the list of FDA formulate
2	MacLennan 1968	Definition of constipation was not clear
3	Williamson 1975	Full-text article was not available
4	Wojcicki 1975	Full-text article was not available
5	Marchesi 1982	Written in Italy. Full-text article was not available
6	Doffoel 1990	Written in French
7	Snustad 1991	Full-text article was not available
8	Ling 1992	Not a randomize controlled trial
9	Teuri 1998	Not pharmacologic intervention (prebiotics)
10	Howard 2000	Not pharmacologic intervention (dietary supplements)
11	Kim 2005	Not pharmacologic intervention (abdominal massage)
12	Wisten 2005	Not pharmacologic intervention (fruit and fiber)
13	Bub 2006	Not pharmacologic intervention (herbal supplements)
14	Chin 2006	Not pharmacologic intervention (physical training)
15	Ueno 2006	No control arm
16	Hale 2007	Not pharmacologic intervention (natural mixture)
17	Pitaka 2007	Not pharmacologic intervention (fermented cereal)
18	Sairanen 2007	Not pharmacologic intervention (yoghurt with prebiotics)
19	Simon 2009	Not pharmacologic intervention (behavioral therapy)
20	Schnelle 2010	Endpoint was improvement in fecal incontinence Intervention are not clearly described
21	Huang 2011	Not pharmacologic intervention (herbal medication)
22	Marteau 2011	Not pharmacologic intervention (chicory inulin supplement)
23	Mun 2011	Not pharmacologic intervention (carbonated water)
24	Yen 2011	Not pharmacologic intervention (isomalto-oligosaccharide)
25	Yen 2011	Not pharmacologic intervention (fructo-oligosaccharide)
26	Hunag 2012	Not pharmacologic intervention (herbal medication)
27	Kondo 2013	Different inclusion criteria (tube feeding patients)
28	Li 2014	Not pharmacologic intervention (auricular pressure)
29	Yeun 2016	Not pharmacologic intervention (probiotics)
30	Konradsen 2017	Not pharmacologic intervention (home care nursing)
31	Fang 2017	Written in Chinese
32	Simon 2017	Not pharmacologic intervention (biofeedback therapy)

FDA, Food and Drug Administration.

Supplementary Table 2. Quality Assessment for Cross-over Study

Study	Appropriate cross-over design	Randomized treatment order	Carry-over effect	Unbiased data	Allocation concealment	Blinding	Incomplete outcome data	Selective outcome reporting	Other bias
Ewerth et al, ¹⁸ 1980	Low	Unclear	Low	Unclear	High	Low	Low	Low	Unclear
Cheskin et al, ²¹ 1995	Low	Unclear	Unclear	Unclear	High	High	Unclear	Low	Unclear
Chokhavatia et al, ²² 1988	Low	Unclear	Unclear	Unclear	Unclear	High	Unclear	Low	Unclear
Vanderdonckt et al, ²⁵ 1990	Low	Unclear	Unclear	Unclear	High	Low	Unclear	Low	Unclear
Lederle et al, ²⁷ 1990	Low	Unclear	Unclear	Unclear	High	High	Low	Low	Unclear
Hyland and Foran, ³⁰ 1968	Unclear	Unclear	Unclear	High	High	Low	Low	Low	Unclear
Kinnunen and Salokannel, ³² 1987	Low	Unclear	Unclear	Unclear	High	Unclear	Low	Low	Unclear
Kinnunen et al, ³³ 1993	Low	Unclear	Unclear	Low	High	High	Low	Low	Unclear
Passmore et al, ³⁴ 1993	Low	Low	Unclear	Unclear	Unclear	Low	Low	Low	Unclear
Pers and Pers, ³⁵ 1983	Low	Unclear	High	Low	Unclear	Unclear	Low	Low	Unclear

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Camilleri 2009	?	?	+	?	+	+	?
Chassagne 2017	+	+	?	+	?	+	+
DiPalma 2007	+	+	+	+	+	+	+
Fain 1978	?	-	-	-	+	?	?
Finlay 1988	?	-	-	-	+	?	?
Menees 2020	+	+	+	+	+	+	+
Muller-Lissner 2010	+	+	+	+	+	+	+
Nakajima 2019	+	+	+	+	+	+	+
Rajala 1988	?	-	?	?	+	+	?
Sanders 1978	?	-	?	-	+	+	?
Seinela 2009	?	?	+	+	+	+	+
Ueno 2006	?	?	+	?	+	+	+
Wesselius 1968	?	?	+	?	+	+	+

Supplementary Figure. Risk of bias of included studies.